NewTimeSpace News: On June 18, 2026, XPENG-W(09868.HK) weakened in afternoon trading. As of 15:31, its intraday quotation stood at HK$51.3, representing a decline of 3.84%. The 13th OTA upgrade for MONA M03 has been fully deployed to all vehicles.
NewTimeSpace (newtimespace.com) News: On June 18, 2026, the chip sector continued to strengthen as SMIC (00981.HK) fluctuated upward. As of 1:43 PM, the company's share price was quoted at HK$78.250, up 3.30%.
the Shanghai Stock Exchange (SSE) issued the Application Guidelines No. 10 for Issuance and Listing Review Rules of the Shanghai Stock Exchange — Application of the Fifth Set of Listing Standards of the Science and Technology Innovation Board by Artificial Intelligence Large Model Enterprises (hereinafter referred to as the "Guidelines No. 10")This expansion into the AI large model sector opens up a direct A-share listing channel for a massive number of high-quality large model enterprises that have not yet turned a profit but possess core technologies.
Newtimespace.com reports: Crealights Technology (1191.HK) launches its global offering of approximately 13.43 million H-shares at an offer price of HK$114.00 per share. The Hong Kong public subscription runs from June 18 to June 24, with an expected listing date of June 29. Huatai International serves as the sole sponsor.
NewTimeSpace News: Fosun Pharma announced on June 17 that its controlled subsidiary Henlius has received approval from the National Medical Products Administration (NMPA) to conduct Phase I clinical trials for its self-developed HLX3902 Injection (STEAP1×CD3×CD28 trispecific antibody) in the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors.
NewTimeSpace News: Shanghai Henlius Biotech, Ltd. (02696.HK) announced on 17 June that the Phase I clinical trial application for self-developed HLX3902 Injection, a STEAP1xCD3xCD28 trispecific antibody, has been approved by NMPA for metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumors. The product simultaneously targets STEAP1, CD3 and CD28 to boost T-cell anti-tumor activity, with promising anti-tumor efficacy and safety demonstrated in preclinical studies. No trispecific antibodies targeting the three above antigens have been launched globally to date. The Company cautions there is uncertainty over successful R&D and commercialization of HLX3902. The candidate also obtained Australian clinical trial notification clearance in May 2026.
On June 17, Hong Kong stocks saw narrow consolidation, but the LLM and semiconductor supply chains erupted. ZHIPU AI surged over 12% following the launch and open-sourcing of its GLM-5.2 flagship model, which ranked first globally on the Code Arena benchmark. KUAISHOU-W jumped 7.3% on rumors of a USD 2 billion financing round for Kling AI, while the memory and PCB sectors soared amid price hikes and shortage forecasts. In major industry developments, the CSRC expanded the STAR Market's fifth listing standard to accommodate pre-revenue AI LLM companies, clearing regulatory hurdles for IPOs. Meanwhile, to mitigate soaring compute costs, Microsoft's Copilot Cowork is pivoting to usage-based pricing and exploring cost-effective open-source alternatives like DeepSeek V4.
NewTimeSpace News: Shanghai Henlius Biotech, Ltd. (02696.HK) announced on 17 June that Hanbeiyou (pertuzumab injection) has passed GMP compliance inspection issued by Shanghai Municipal Drug Administration. The Songjiang manufacturing base is now qualified for domestic commercial production of the product. Independently developed pertuzumab biosimilar for HER2-positive breast cancer, Hanbeiyou has obtained marketing approvals in China, the US and EU. Domestic sales of pertuzumab products reached approximately RMB2.728 billion in 2025 per IQVIA CHPA data.
NewTimeSpace News: Giant Biogene Holding Co., Ltd. (02367.HK) announced that its wholly-owned subsidiary Shaanxi Giant Biotech Co., Ltd. has received the Medical Device Registration Certificate issued by the National Medical Products Administration (NMPA) for its Cross-linked Recombinant Collagen Implant. The product is designed for intradermal dermal injection and filling of the neck to correct moderate-to-severe horizontal neck lines, making it the world’s first cross-linked recombinant Type III collagen filler dedicated to neck wrinkle treatment.
NewTimeSpace News: As of 15:33 on June 17, 2026, BIDU-SW(09888.HK) trended stronger, quoting HK$111.8 intra-day, representing a 0.99% gain. Apollo Go, Baidu’s autonomous driving arm, has officially entered Switzerland. Its self-driving service AmiGo, developed jointly with local public transport operator PostBus, has started public road testing.
NewTimeSpace (newtimespace.com) News: On June 17, 2026, the chip sector fluctuated and strengthened. The share price of Hua Hong Semiconductor Limited (01347.HK) rose substantially. As of 13:44 PM, the company's share price was quoted at HK$156.200, up 6.48%.
Mininglamp Technology (2718.HK) Under the trend where Edge AI transitions from a "concept" to a "trillion-dollar industrial blueprint" and AI Agents race from a "tens-of-billions track" toward a "three-hundred-billion market," the company is validating a core proposition through its differentiated path of "Scaling Out."
NewTimeSpace (newtimespace.com) News: On June 17, 2026, the humanoid robot sector fluctuated and weakened. Midea Group (00300.HK) fluctuated downward, with the company's share price quoted at HK$89.250, down 1.00% as of 13:17 PM.
Choice data shows that on June 16, 2026,First Seafront Artificial Intelligence Dynamic Allocation Hybrid Fund-A (001986) and First Seafront Artificial Intelligence Dynamic Allocation Hybrid Fund-C (023286) recorded gains of 5.35% respectively. Over the past three months,First Seafront Artificial Intelligence Dynamic Allocation Hybrid Fund-A (001986) and Mixed C (023286) have jumped by 78.10% and 77.92% respectively.
Newtimespace.com reports: MicroPort MedBot (2252.HK) announced that Toumo endoscopic surgical robot global commercial orders have exceeded 300 units, with H1 new orders surpassing full-year 2024 total and comprehensive orders nearing 400 units. Toumo has achieved commercial installation in over 60 countries and recently completed the world's first Starlink satellite-enabled robotic remote surgery, with annual production capacity exceeding 500 units.
NewTimesSpace (newtimespace.com) reports: Keytop Parking (2272.HK) launched its subscription on June 17, offering approximately 10.11 million H shares globally at HK$39.55 per share. The entry fee for one board lot of 60 shares is approximately HK$2,397. The listing is expected on June 26, with CICC and CMBC Capital serving as joint sponsors.
